256 related articles for article (PubMed ID: 19520778)
1. Epigenetic alterations in human prostate cancers.
Nelson WG; De Marzo AM; Yegnasubramanian S
Endocrinology; 2009 Sep; 150(9):3991-4002. PubMed ID: 19520778
[TBL] [Abstract][Full Text] [Related]
2. Abnormal DNA methylation, epigenetics, and prostate cancer.
Nelson WG; Yegnasubramanian S; Agoston AT; Bastian PJ; Lee BH; Nakayama M; De Marzo AM
Front Biosci; 2007 May; 12():4254-66. PubMed ID: 17485372
[TBL] [Abstract][Full Text] [Related]
3. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide.
Lin X; Asgari K; Putzi MJ; Gage WR; Yu X; Cornblatt BS; Kumar A; Piantadosi S; DeWeese TL; De Marzo AM; Nelson WG
Cancer Res; 2001 Dec; 61(24):8611-6. PubMed ID: 11751372
[TBL] [Abstract][Full Text] [Related]
4. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
[TBL] [Abstract][Full Text] [Related]
5. Beyond the island: epigenetic biomarkers of colorectal and prostate cancer.
Savio AJ; Bapat B
Methods Mol Biol; 2015; 1238():103-24. PubMed ID: 25421657
[TBL] [Abstract][Full Text] [Related]
6. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer prevention.
Nelson WG
Curr Opin Urol; 2007 May; 17(3):157-67. PubMed ID: 17414513
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation changes in prostate cancer.
Goering W; Kloth M; Schulz WA
Methods Mol Biol; 2012; 863():47-66. PubMed ID: 22359287
[TBL] [Abstract][Full Text] [Related]
9. [CpG island hypermethylation of the DNA. Perspectives of a molecular biomarker for prostate cancer].
Bastian PJ; Ellinger J; von Rücker A; Müller SC; Yegnasubramanian S; Nelson WG; Stief CG
Urologe A; 2008 Sep; 47(9):1205-7. PubMed ID: 18651120
[TBL] [Abstract][Full Text] [Related]
10. The importance of DNA methylation in prostate cancer development.
Massie CE; Mills IG; Lynch AG
J Steroid Biochem Mol Biol; 2017 Feb; 166():1-15. PubMed ID: 27117390
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics of prostate cancer: beyond DNA methylation.
Schulz WA; Hatina J
J Cell Mol Med; 2006; 10(1):100-25. PubMed ID: 16563224
[TBL] [Abstract][Full Text] [Related]
12. Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
Lee J; Lee MS; Jeoung DI; Kim YM; Lee H
Prostate; 2017 Mar; 77(4):350-360. PubMed ID: 27813113
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic CpG Methylation of the Promoter and Reactivation of the Expression of GSTP1 by Astaxanthin in Human Prostate LNCaP Cells.
Yang Y; Fuentes F; Shu L; Wang C; Pung D; Li W; Zhang C; Guo Y; Kong AN
AAPS J; 2017 Mar; 19(2):421-430. PubMed ID: 27913949
[TBL] [Abstract][Full Text] [Related]
14. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer.
Nakayama M; Gonzalgo ML; Yegnasubramanian S; Lin X; De Marzo AM; Nelson WG
J Cell Biochem; 2004 Feb; 91(3):540-52. PubMed ID: 14755684
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer epigenetics and its clinical implications.
Yegnasubramanian S
Asian J Androl; 2016; 18(4):549-58. PubMed ID: 27212125
[TBL] [Abstract][Full Text] [Related]
16. Epigenetics as a Key Factor in Prostate Cancer.
Enikeeva K; Rafikova G; Sharifyanova Y; Mulyukova D; Vanzin A; Pavlov V
Adv Biol (Weinh); 2024 May; 8(5):e2300520. PubMed ID: 38379272
[TBL] [Abstract][Full Text] [Related]
17. piR-31470 epigenetically suppresses the expression of glutathione S-transferase pi 1 in prostate cancer via DNA methylation.
Zhang L; Meng X; Pan C; Qu F; Gan W; Xiang Z; Han X; Li D
Cell Signal; 2020 Mar; 67():109501. PubMed ID: 31837464
[TBL] [Abstract][Full Text] [Related]
18. Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007.
Meiers I; Shanks JH; Bostwick DG
Pathology; 2007 Jun; 39(3):299-304. PubMed ID: 17558856
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
